A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

NCT01551459 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG: Dacarbazine
DRUG: Sunitinib

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Collaborators

[object Object]
[object Object]